2026 Annual Meeting | C62 - Mild Cognitive Impairment/Subjective Cognitive Impairment

Date Sunday 04/19/26

Time 01:00 PM - 03:00 PM CDT Add To Calendar

Location McCormick Place West | W375c

Supported By This program is supported in part by an educational grant from Eisai Inc.

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Oscar L. Lopez, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives There have been significant advances in the clinical diagnosis, treatment, and management of mild cognitive impairment (MCI) patients, especially of those with MCI due to Alzheimer’s disease (AD). This is a new landscape for neurologists that must adapt to the rapid changes in treatment guidelines and diagnosis by clinical, neuroimaging, and fluid biomarkers. This course provides neurologists with current conceptual approaches of the syndrome, reviews the non-AD forms of MCI, and discusses clinical scenarios of treatment response. The goal of this course is to increase the understanding of the heterogeneity of the MCI syndrome, from the initial clinical exam to initiating management strategies. Case studies will be used to highlight some of these issues.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Quality Improvement

Program Level Intermediate

Program Tracks Brain Health

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM CDT	Introduction	Introduction Oscar L. Lopez, MD, FAAN
01:05 PM - 01:40 PM CDT	Speaker	MCI Overview and Diagnosis Ronald C. Petersen, MD, PhD, FAAN
01:40 PM - 02:10 PM CDT	Speaker	MCI in Non-AD Disorders Oscar L. Lopez, MD, FAAN
02:10 PM - 02:40 PM CDT	Speaker	Treatment of MCI David J. Gill, MD, FAAN
02:40 PM - 03:00 PM CDT	Q&A	Questions and Answers Oscar L. Lopez, MD, FAAN, David J. Gill, MD, FAAN, Ronald C. Petersen, MD, PhD, FAAN

Faculty Disclosures
David J. Gill, MD, FAAN	Dr. Gill has nothing to disclose.
Oscar L. Lopez, MD, FAAN	Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acumen.
Ronald C. Petersen, MD, PhD, FAAN	Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.